Objective: The aim of the present study was to investigate the combined impact of visceral adipose tissue (VAT) and secretory group IIA phospholipase A 2 (sPLA 2 -IIA) concentrations on the atherogenicity of low-density lipoprotein (LDL) particles among men. Subjects: Analyses were conducted in 74 mid-obese healthy men (age: (mean7s.d.) 37.9711.7 years). Methods: Plasma levels of sPLA 2 -IIA were measured with a commercial ELISA and VAT levels were assessed by computed tomography. Distinct subpopulations of LDL particles were characterized from whole plasma using nondenaturating 2-16% gradient gel electrophoresis. Results: Data indicated that plasma sPLA 2 -IIA levels were approximately 29% (P ¼ 0.007) higher among men characterized by a higher accumulation of VAT (4142 vs p142 cm 2 ). Men having high plasma sPLA 2 -IIA levels (X127.2 ng/dl, the median value), were characterized by higher levels of plasma cholesterol (C) and apolipoprotein (apo) B, LDL-C, LDL-apoB, oxidized LDL (OxLDL) and by smaller LDL particles compared to men with sPLA 2 -IIAo127.2 ng/dl. Multiple regression analyses showed that plasma triglycerides and sPLA 2 -IIA levels explained 22.7 and 11.8% of the variance in LDL peak particle size, respectively. Levels of VAT and of sPLA 2 -IIA were the strongest correlates of OxLDL levels explaining, respectively, 15.0 and 5.5% of their variability. Conclusion: Both VAT and sPLA 2 -IIA levels modulate the atherogenecity of LDL by accounting for the reduction in their size and their susceptibility to oxidation.
Introduction
Epidemiological studies have reported an increased coronary heart disease (CHD) risk among individuals with small dense low-density lipoproteins (LDL) particles. 1 Recent research on the lipid composition, charge and susceptibility of LDL to oxidation has led to a better understanding of their role in the etiology of atherosclerosis. The phospholipid-depleted surface monolayer of small dense LDL compared with large LDL particles, is responsible for a change in the conformation of apolipoprotein (apo) B-100, which leads to more exposure of proteoglycan-binding regions. 2 The diminished affinity of small dense LDL towards the LDL receptor results in longer residence time of LDL, 3 which increases their susceptibility to oxidation, a factor of significance in atherosclerosis. Enzymes involved in lipoprotein remodeling such as hepatic lipase (HL) and lipoprotein lipase (LPL) have been shown to modulate the small, dense LDL phenotype. 4, 5 The phospholipase (PLA 2 ) family comprises a group of enzymes that hydrolyze the sn-2 ester bond in the glyceroacyl phospholipids present in lipoproteins and cell membranes. 6 Group IIA (-IIA) sPLA 2 is an acute-phase protein for which plasma levels were reported to correlate with that of C-reactive protein (CRP) and to be an independent risk factor and predictor of coronary heart disease. 7 Immunohistochemical studies have shown that secretory group IIA phospholipase A2 (sPLA 2 -IIA) is present in normal arteries, and that, in early and late atherosclerotic lesions, its extracellular distribution and level of cell expression is increased, suggesting that the enzyme is implicated in atherogenesis. 8 Exogenous addition of sPLA 2 -IIA to total human plasma has been shown to promote the hydrolysis of phospholipids at the surface of LDL, thereby reducing their size and increasing their density. 9 Hypertriglyceridemia, low HDL (high-density lipoprotein) and small dense LDL particles are common lipid abnormalities in individuals with insulin resistance and type 2 diabetes mellitus. 10 In healthy volunteers, partly oxidized LDL concentrations are correlated with insulin resistance and its metabolic consequences. 11 Susceptibility of LDL to oxidation has also been associated with increasing levels of total and abdominal adiposity.
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In the present study, we investigated how variations in abdominal obesity relates to plasma sPLA 2 -IIA levels and its impact on the composition of LDL particles in sedentary, overweight healthy men. We also evaluated the combined impact of visceral adipose tissue accumulation and plasma levels of sPLA 2 -IIA on the atherogenecity of LDL particles.
Materials and methods

Subjects
A sample of 80 sedentary men was recruited through the media in the Québec City metropolitan area. Individuals with endocrine, cardiovascular, hepatic and renal disorders as well as those using medication affecting lipid metabolism, smokers, individuals with excessive alcohol intake and with unstable weight within the year preceding the study were excluded of the study. Each participant signed a consent form approved by the Clinical Research Ethics Committee of Laval University.
Anthropometrics and body composition measurements
Body weight and waist circumference were measured according to standardized procedures. 13 Total, subcutaneous and visceral adipose tissue (VAT) accumulation was assessed by computed tomography as described previously. 14 
Laboratory methods
Blood samples were collected after a 12-h fast. Samples were then immediately centrifuged at 41C for 10 min at 1500g, and stored at 41C until processed. Plasma lipid and apolipoprotein levels were measured according to standardized procedures as detailed elsewhere. 15 Cholesterol and TG levels were determined by enzymatic methods using the Technicon RA-500 analyzer (Bayer Corporation Inc., Tarrytown, NY, USA), as previously described. 16 Plasma very LDLs in the infranatant were isolated by ultracentrifugation, and the HDL fraction was obtained after precipitaion of LDLs with heparin and MnCl 2 . 17 Total apoB and LDL-apoB levels were measured by nephelometry on a Behring BN-100 nephelometer (Dade Behring, Mississauga, ON, Canada) and VLDL-apoB levels were obtained by substracting LDLapoB from total plasma apoB concentrations. Fasting plasma glucose concentrations were determined with a glucose oxidase assay from Sigma (St Louis, MO, USA). 18 Plasma insulin concentrations were measured by a commercial double-antibody radioimmunoassay (Linco, St Louis, MO, USA), which shows essentially no crossreaction with proinsulin. 19 Distinct subpopulations of LDL particles were separated in whole plasma using nondenaturating 2-16% gradient gel electrophoresis as previously described. 1 Lowdensity lipoprotein peak particle diameter was identified as the most important subclass of LDL in each individual and was calculated from calibration curves using plasma standards of known diameter. The CV of the calculated particle diameters was estimated to be o1%. The relative proportion of LDL particles with a diametero255 Å (LDL% o255 Å ) was ascertained by computing the relative area of the densiometric scano255 Å . The absolute concentration of cholesterol among particleso255 Å (LDL-C o255 Å ) was estimated by multiplying the total plasma LDL cholesterol levels by the relative proportion of LDL with a diametero255 Å . A similar approach was used to assess the relative proportion of LDL particles with a diameter 4260 Å (LDL% 4260 Å ) and absolute concentrations of cholesterol in particles with a diameter 4260 Å (LDL-C 4260 Å ). 1 Oxidized LDL (OxLDL) concentrations were measured using a commercial ELISA according to the manufacturer's instructions (Alpco Diagnostics, Windham, NH). C-reactive protein levels were measured with a highly sensitive commercial immunoassay (Dade Behring, Mississauga, ON, Canada) as described previously. 20 Plasma interleukin-6 (IL-6) levels were measured on baseline samples using a commercially available ELISA (R&D Systems, Minneapolis, MN, USA).
Intravascular enzyme activities and mass
Plasma postheparin (60 IU/kg body weight) LPL and HL activities were measured after a 12-h overnight fast. LPL and HL activities were determined in postheparin plasma after preincubation with SDS, 21 as previously described by Watson et al. 22 Activities were expressed as micromoles of free fatty acids released per milliliter of plasma per hour. Plasma CETP mass concentration was determined by a commercial sandwich ELISA immunoassay kit (Wako Chemicals Inc., Richmond, VA, USA). Plasma levels of sPLA 2 -IIA were measured using a commercial assay according to the manufacturers' procedure (Cayman Chemical, Ann Arbor, MI, USA). This is an ELISA system with a monoclonal antibody for capture and a polyclonal antibody with colorimetric detection. The coefficient of variation for the determination of sPLA 2 -IIA was 7%.
Statistical analysis
Data were analyzed using SAS (version 8.2, SAS Institute, Cary, NC, USA). Subgroups of subjects with high or low plasma sPLA 2 -IIA levels were arbitrarily defined using the median of the distribution (127.2 ng/dl). Differences between sPLA 2 -IIA mass groups were assessed by analysis of variance. Multiple comparisons among groups were performed using the post hoc Duncan multiple range test.
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Spearman's correlation coefficients were calculated to test for associations between plasma sPLA 2 -IIA levels and anthropometric variables, lipid-lipoprotein variables and LDL electrophoretic characteristics. Subjects having plasma CRP levels higher than 10 mg/l, plasma IL-6 levels higher than 10 mg/l and/or plasma sPLA 2 -IIA levels above 900 ng/dl were not included in the present analysis (N ¼ 6). Thus, analyses were conducted in a sample of 74 men. Stepwise and multiple linear regression analysis were used to identify independent correlates of LDL peak particle size and OxLDL levels. In the first model, the contribution of plasma sPLA 2 -IIA and TG levels, VAT levels and age were investigated. In the second model, LPL and HL activities and CETP mass were further added to the model.
Results
Men investigated in the present study (N ¼ 74), were aged between 20 and 56 years and were near the obese criteria as a group with a mean body mass index (BMI) of 29. 875.2 kg/ m 2 ( Table 1) . They had a relatively normal plasma lipid profile as a group with mean plasma LDL-C, TG and HDL-C levels of 3.0070.88, 1.4570.71 and 1.0470.18 mmol/l, respectively. Plasma sPLA 2 -IIA concentrations were positively correlated with various indices of obesity, fasting plasma insulin levels, total cholesterol, total apoB, CRP and IL-6 levels among this sample of men (Table 2 ). Figure 1 illustrates age-adjusted correlations between plasma sPLA 2 -IIA levels and VAT levels (panel a), plasma OxLDL levels (panel b) and plasma LDL peak particle size (panel c). When further adjusted for IL-6, the positive association between plasma sPLA 2 -IIA and VAT levels was no longer significant (R ¼ 0.19, P ¼ 0.11, not shown). However, the correlations found between plasma sPLA 2 -IIA and the lipid variables remained significant when adjsuted for IL-6 (not shown). Additional correlations were tested in these subjects. Visceral adipose tissue levels were positively and significantly correlated with various indices of obesity, fasting plasma insulin and glucose levels, CRP and IL-6 levels. Visceral adipose tissue levels correlated also positively with LDL-C, LDL-apoB, OxLDL and the proportion of small LDL particles (not shown). Plasma LDL size correlated significantly and positively with LPL activity but not with HL activity or CETP mass. Plasma OxLDL did not correlate with LPL and HL activities or with CETP mass (not shown). Table 3 shows the lipoprotein-lipid profile according to plasma levels of sPLA 2 -IIA, which were arbitrarily defined as low or high based on the median of the distribution in the sample of 74 men (o or X127.2 ng/dl). Men having high plasma sPLA 2 -IIA levels were characterized by higher plasma total cholesterol, total apoB, plasma LDL-C, LDL-apoB and OxLDL levels, smaller LDL particles along with a higher proportion of small LDL particles (o255 Å ) and higher cholesterol content within small LDL particles (LDL-C o255 Å ). These differences between the high and low sPLA 2 -IIA groups remained significant when further adjusted for age.
The association between VAT area and plasma concentrations of sPLA 2 -IIA was investigated further by defining groups on the basis of the median of the distribution of VAT levels, below or above the median (142 cm 2 ) (Figure 2 ). Plasma sPLA 2 -IIA levels were about 29% higher (P ¼ 0.007) among men with high VAT levels compared to men with low VAT levels. Obesity, sPLA 2 
The combined impact of plasma VAT accumulation and plasma sPLA 2 -IIA levels on the LDL profile was investigated by dividing participants on the basis of the median of the distribution of sPLA 2 -IIA concentrations and VAT levels. Figure 3 shows that among subjects with relatively low levels of VAT, an elevated plasma sPLA 2 -IIA concentration was associated with reduced LDL peak particle diameter, which was similar to the LDL peak particle diameter observed in individuals with arbitrarily high VAT levels (panel a). Plasma OxLDL levels were significantly higher among the high VAT/ high sPLA 2 -IIA group compared to the other three groups of men (panel b). High VAT levels were associated with a deleterious elevation in LDL-C o255 Å levels irrespective of plasma sPLA2-IIA levels (panel c).
The combined impact of VAT levels and plasma IL-6 levels on sPLA 2 -IIA levels was investigated by dividing participants on the basis of the median of the distribution of VAT levels and IL-6 levels (o or X1.5 mg/l). Figure 4 shows that among subjects with relatively high plasma IL-6 levels, visceral adiposity had no further impact on plasma sPLA 2 -IIA concentrations.
Multiple regression analyses were conducted to sort out the contribution of age, VAT levels, plasma TG and sPLA 2 -IIA levels to the variance in LDL peak particle size and in OxLDL levels. As shown in Table 4 , plasma sPLA 2 -IIA levels explained 11.8% (P ¼ 0.0008) and 5.5% (P ¼ 0.06) of the variance in LDL peak particle size and plasma OxLDL levels, respectively. Plasma TG levels remained the major contributor to the variance of LDL peak particle size, further explaining 22.7% (Po0.0001) with VAT area predicting an additional 15.0% (P ¼ 0.003) of the variation in OxLDL levels. When entered into the model, LPL activity accounted for 5.6% (P ¼ 0.01) of the variation in LDL size and CETP levels contributed to further explaining 4.6% (P ¼ 0.02) of the variance in LDL size. Neither of these variables correlated with OxLDL levels. Furthermore, HL activity did not further explain variations in LDL peak particle size or oxLDL levels in this model. Subanalyzes indicated that the associations between sPLA 2 -IIA and LDL size and oxidized LDL in a multivariate model was significant in subjects with low VAT levels (p142 cm 2 ) but not significant in those with high VAT levels (4142 cm 2 ) (not shown). Also, we have examined how total and subcutaneous adipose tissue could alter the association between sPLA 2 -IIA and LDL peak particle size and OxLDL. When we replaced VAT by total or subcutaneous adipose tissue in the multivariate model, plasma sPLA 2 -IIA remained an independent predictor of LDL size and OxLDL. Thus, total and subcutaneous adipose tissue did not contribute independently to variations in LDL size or OxLDL.
Discussion
The cholesterol content of LDL represents only one aspect of this atherogenic lipoprotein subclass. The atherogenecity of small dense LDL could be attributable to a facilitated uptake by arterial tissue compared to larger LDL. 24 Smaller LDL particles also have a reduced affinity to the LDL receptor and bind with a greater affinity to proteoglycans. 25 Moreover, susceptibility to oxidation increases and antioxidant concentration decreases with decreasing LDL size. 26 We therefore investigated how sPLA 2 -IIA contributed to the atherogenecity of LDL particles, particularly in the context of visceral obesity. Obesity, sPLA 2 -IIA and LDL
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Data from the present study indicated that plasma sPLA 2 -IIA levels were correlated positively with obesity indices including VAT levels. Our data confirmed previous observations by showing that men with arbitrarily high plasma sPLA 2 -IIA levels had a more atherogenic LDL profile compared to men with low sPLA 2 -IIA levels as depicted by higher plasma LDL-C, LDL-apoB levels and OxLDL concentrations and smaller LDL particles. Data of the present study further revealed that sPLA 2 -IIA levels remained a key determinant of the variation in LDL size even after adjustment for plasma TG levels and VAT levels. Finally, we observed that among men with low VAT levels (p142 cm 2 ), plasma sPLA 2 -IIA concentrations modulated LDL particle phenotype thereby contributing to a more atherogenic LDL profile in this apparently low risk group. These observations are somewhat discordant with results from the EPIC-Norfolk study that have shown in men that total and LDL cholesterol levels were similar between sPLA 2 -IIA quartiles. 27 However, results from in vitro studies have shown that treatment of LDL with sPLA 2 -IIA produces small dense LDL 28 and that sPLA 2 -IIA-treated LDL particles are more susceptible to peroxidation. 29 Body mass index correlated positively with plasma sPLA 2 -IIA levels in the present study, an observation that is consistent with what has been reported by other groups. 30, 31 We also observed a positive correlation between VAT and plasma sPLA 2 -IIA levels among these men. Specifically, plasma sPLA 2 -IIA levels were approximately 29% higher among men with a high accumulation of VAT (upper 50th percentile of VAT levels) compared to men with relatively Low VAT (N ¼ 38) or high VAT (N ¼ 36) was arbitrarily defined according to the 50th percentile of VAT levels (p or 4142 cm 2 ). P-values are adjusted for age and correspond to the P-value from the ANOVA performed on logtransformed sPLA 2 -IIA values.
Obesity, sPLA 2 -IIA and LDL M-E Paradis et al lower VAT levels. Adipose tissue is now recognized as a dynamic system with depot-specific differences and various biological functions. 32 Indeed, it has been shown that omental adipose tissue (one of the most active adipose tissue composing VAT) expresses and produces two to three times more IL-6 than subcutaneous fat. 33 As peripheral fat contributes to circulating IL-6 concentrations 34 which are known to regulate sPLA 2 -IIA, 35 we hypothesize that adipocytes of the visceral compartment may play a role in the inflammatory signaling process enhancing sPLA 2 -IIA levels.
In agreement with this hypothesis, we observed that elevated IL-6 levels (X1.5 mg/l, the median value) were associated with elevated plasma sPLA 2 -IIA levels irrespective of VAT levels. On the other hand, in the context of an apparently reduced inflammatory state (IL-6o1.5 mg/l), high VAT levels were associated with intermediate plasma sPLA 2 -IIA levels, with values being higher compared with men in the low IL-6/ low VAT group but lower compared with men in the high IL-6 groups irrespective of VAT accumulation. The limited number of subjects in each of the IL-6/VAT subgroups did not allow us to detect a significant multiplicative interaction between VAT levels and IL-6 levels in determining sPLA 2 -IIA levels.
Results from the present study suggest that both VAT levels and sPLA 2 -IIA levels may play a role in the atherogenicity of LDL, contributing to reduce LDL particle size and increase OxLDL concentrations. We hypothesize that VAT influences circulating sPLA 2 -IIA levels at least partly through its modulating effect on proinflammatory cytokines released by adipocytes. This hypothesis remains to be elucidated at a molecular level and to be replicated in larger cohorts of subjects. Also, women should be included in future analyses The median value (127.2 ng/dl) was used to classify subjects with low (') or high (&) plasma sPLA 2 -IIA levels. The median value (142 cm 2 ) was used to classify subjects with low or high VAT accumulation. Data are presented as mean7standard error (s.e.). P-values presented at the corner of the graphs are adjusted for age and correspond to the P-value from the ANOVA performed on log-transformed (oxLDL) values. The significant difference with the corresponding group is indicated above the s.e. Figure 4 Combined impact of visceral adipose tissue (VAT) accumulation and interleukin-6 (IL-6) levels on plasma secretory group IIA phospholipase A 2 (sPLA 2 -IIA) levels. The median value (142 cm 2 ) was used to classify subjects with low (') or high (&) VAT levels and the 1.5 mg/l value (median) was used to classify subjects with low or high IL-6 levels. The % of difference in plasma sPLA 2 -IIA levels between each group and the control group (low VAT/ low IL-6) is indicated at the top of each bar. Data are presented as means7standard error (s.e.). P-value presented in the corner of the graph corresponds to the P-value from the ANOVA performed on log-transformed sPLA 2 -IIA values and adjusted for age. The significant difference with the corresponding group is indicated above the s.e.
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